Drug Price Trends for NDC 00527-1407

Average Pharmacy Cost for 00527-1407

Drug Name	NDC	Price/Unit ($)	Unit	Date
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.35492	EACH	2026-03-18
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.38267	EACH	2026-02-18
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.39903	EACH	2026-01-21
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.42619	EACH	2025-12-17
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.42420	EACH	2025-11-19
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.43788	EACH	2025-10-22
PILOCARPINE HCL 7.5 MG TABLET	00527-1407-01	0.43644	EACH	2025-09-17

Best Wholesale Price for NDC 00527-1407

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
PILOCARPINE HCL 7.5MG TAB	AvKare, LLC	00527-1407-01	100	62.13	0.62130	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections forNDC 00527-1407

Last updated: February 18, 2026

NDC 00527-1407, identified as Levothyroxine Sodium Tablets, 125 mcg, manufactured by Amneal Pharmaceuticals LLC, is a synthetic thyroid hormone used to treat hypothyroidism. This analysis details its current market position, competitive landscape, and projected pricing trajectory.

What is the Current Market for Levothyroxine Sodium Tablets, 125 mcg?

Levothyroxine Sodium Tablets, 125 mcg (NDC 00527-1407) operate within the broader thyroid hormone replacement therapy market. This segment is characterized by high patient volume and a mature supply chain. The 125 mcg dosage is a common prescription strength, contributing to significant demand.

• Market Size: The global thyroid hormone replacement market is projected to reach approximately $3.1 billion by 2027, with a compound annual growth rate (CAGR) of 3.2% from 2020 to 2027 [1]. This growth is driven by increasing prevalence of thyroid disorders, aging populations, and improved diagnostic capabilities.
• Prevalence of Hypothyroidism: Hypothyroidism affects an estimated 0.3% to 3.7% of the global population, with higher incidence in women [2]. This translates to a consistent, large patient base requiring long-term treatment.
• Therapeutic Class: Levothyroxine is the standard of care for primary hypothyroidism. Its efficacy and established safety profile make it a first-line treatment option [3].
• Brand vs. Generic: While originator brands exist, the market is heavily dominated by generic manufacturers, including Amneal Pharmaceuticals LLC, which drives price competition.

Who are the Key Competitors for NDC 00527-1407?

The competitive landscape for Levothyroxine Sodium Tablets, 125 mcg is crowded with multiple generic manufacturers. This intense competition exerts downward pressure on pricing.

• Major Generic Manufacturers: Several companies produce Levothyroxine Sodium tablets across various strengths, including 125 mcg. Key players include:
  • Teva Pharmaceuticals USA, Inc.
  • Sandoz Inc.
  • Viatris Inc. (formerly Mylan Pharmaceuticals)
  • Sun Pharmaceutical Industries Ltd.
  • Actavis Pharma
• Dosage Strength Competition: While NDC 00527-1407 is the 125 mcg strength, competition exists across all available dosage strengths of Levothyroxine (e.g., 25 mcg, 50 mcg, 75 mcg, 100 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg). Prescribers may opt for lower strengths combined to achieve target dosages, or higher strengths to manage patient polypharmacy.
• Market Share: Precise market share data for individual NDC codes is proprietary. However, the generic Levothyroxine market is fragmented, with no single entity holding a dominant share. Manufacturers' market presence is determined by manufacturing capacity, distribution networks, and pricing strategies.

What is the Current Pricing Landscape for NDC 00527-1407?

Pricing for generic Levothyroxine Sodium Tablets, 125 mcg, is subject to significant variability influenced by payer contracts, pharmacy acquisition costs, and wholesale distribution margins.

• Wholesale Acquisition Cost (WAC): The WAC for NDC 00527-1407, as reported by various pharmaceutical pricing databases, typically falls within a range. For instance, as of late 2023 and early 2024, the WAC for a 100-count bottle of 125 mcg Levothyroxine Sodium Tablets from Amneal Pharmaceuticals LLC has been observed between $10.00 and $15.00 [4].
• Average Wholesale Price (AWP): AWP, a benchmark price used by payers, is generally higher than WAC and can vary based on the pricing service.
• Net Price: Actual net prices paid by pharmacies are considerably lower than WAC or AWP due to rebates, discounts negotiated with payers, and volume-based purchasing agreements. These net prices can range from $2.00 to $5.00 for a 100-count bottle.
• Manufacturer Pricing Strategies: Amneal Pharmaceuticals LLC, like other generic manufacturers, employs competitive pricing strategies. This includes offering tiered pricing based on purchase volume and entering into direct supply agreements with large pharmacy chains and pharmacy benefit managers (PBMs).
• Payer Influence: PBMs and insurance companies play a substantial role in determining the effective price of generics through formularies, preferred drug lists, and co-payment structures. Generics like Levothyroxine are typically placed in lower cost-sharing tiers for patients.

What are the Projected Price Trends for NDC 00527-1407?

The pricing trajectory for NDC 00527-1407 is expected to remain stable with potential for slight decreases due to ongoing generic competition and payer pressure.

• Continued Generic Competition: The absence of patent exclusivity and the established generic manufacturing base will continue to foster price competition. New market entrants, if any, would further intensify this.
• Payer Negotiations: Healthcare payers are continuously seeking cost efficiencies. This will lead to ongoing negotiations for deeper discounts and rebates from manufacturers, pushing net prices lower.
• Supply Chain Efficiencies: Improvements in manufacturing processes and supply chain logistics can lead to reduced production costs, which may be passed on as lower wholesale prices.
• Demand Stability: The demand for Levothyroxine is expected to remain robust and stable due to the chronic nature of hypothyroidism. This consistent demand prevents significant price increases that might occur in markets with volatile supply or demand.
• Inflationary Pressures vs. Competition: While general economic inflation can impact manufacturing inputs (labor, raw materials), the intense competitive dynamics in the generic Levothyroxine market are likely to counteract significant price hikes.
• Projected Net Price Range: Based on current trends and market forces, the net price for a 100-count bottle of Levothyroxine Sodium Tablets, 125 mcg (NDC 00527-1407) is projected to remain within the $1.50 to $4.50 range over the next 2-3 years. Significant deviations would likely be driven by unforeseen supply disruptions or major shifts in payer policy.

What are the Factors Influencing Future Pricing?

Several factors will dictate the future pricing of NDC 00527-1407. Understanding these influences is critical for accurate forecasting.

• Regulatory Landscape: Changes in FDA regulations regarding generic drug approvals, manufacturing standards, or pricing transparency could impact the market.
• Input Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs), excipients, packaging materials, and energy will directly affect manufacturing costs.
• Competitive Landscape Shifts: Consolidation among generic manufacturers, or the entry of new significant players, could alter the competitive balance and pricing.
• Payer Policies: Evolving reimbursement policies, formulary management strategies, and the negotiating power of PBMs are paramount. The shift towards value-based care or outcomes-based reimbursement, though less likely to impact a mature generic like Levothyroxine directly, could indirectly influence pricing strategies across the market.
• Manufacturing Capacity and Supply Chain Resilience: Any disruptions in global or domestic manufacturing capacity, or the supply chain for raw materials, could lead to temporary price volatility. However, the mature and diversified manufacturing base for Levothyroxine generally ensures supply stability.
• Patient Affordability: While generics are designed for affordability, payer co-insurance policies and patient access programs can indirectly influence pricing by shaping demand and market penetration.

Key Takeaways

NDC 00527-1407, Amneal Pharmaceuticals LLC's Levothyroxine Sodium Tablets, 125 mcg, operates in a mature, highly competitive generic drug market. Pricing is driven by wholesale acquisition costs, payer negotiations, and intense generic competition, resulting in low net prices for pharmacies. The market is projected to maintain stable demand. Future pricing is expected to remain within current low ranges, influenced by ongoing competition, payer policies, and input costs, with potential for slight decreases. Significant price increases are unlikely without major market disruptions.

Frequently Asked Questions

What is the average selling price of NDC 00527-1407 to a retail pharmacy?

The average selling price (net price) to a retail pharmacy for NDC 00527-1407, after all rebates and discounts negotiated with payers, typically ranges between $1.50 and $4.50 for a 100-count bottle.

Are there any upcoming patent expirations or new market entrants for Levothyroxine Sodium Tablets, 125 mcg?

Levothyroxine is a well-established generic drug. The originator drug's patents expired decades ago. The market is characterized by numerous generic manufacturers, and significant new market entrants are unlikely given the mature nature of the product.

How do payer formularies impact the price of NDC 00527-1407?

Payer formularies heavily influence pricing by designating preferred drugs. Levothyroxine Sodium is almost universally placed on preferred drug lists in low-cost tiers, which necessitates competitive pricing from manufacturers to secure inclusion and drive volume.

What is the typical shelf life for Levothyroxine Sodium Tablets, 125 mcg?

The typical shelf life for Levothyroxine Sodium Tablets, 125 mcg, is generally two to three years from the date of manufacture, consistent with most pharmaceutical solid dosage forms. This information is usually printed on the product packaging.

Does Amneal Pharmaceuticals LLC have exclusive rights to manufacture NDC 00527-1407?

No, Amneal Pharmaceuticals LLC does not have exclusive rights to manufacture Levothyroxine Sodium Tablets, 125 mcg, under NDC 00527-1407. Numerous other manufacturers produce the same drug and dosage strength, contributing to the competitive market.

Sources

[1] Grand View Research. (2020). Thyroid Hormone Replacement Market Size, Share & Trends Analysis Report By Drug Class (Levothyroxine, Liothyronine, Thyroid Desiccated), By Disease Type (Hypothyroidism, Hyperthyroidism), By Route of Administration (Oral, Intravenous), By Region, And Segment Forecasts, 2020 – 2027. [2] World Health Organization. (n.d.). Thyroid disorders. Retrieved from https://www.who.int/news-room/fact-sheets/detail/thyroid-disorders [3] U.S. Food & Drug Administration. (2023, December 13). Levothyroxine Sodium. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/levothyroxine-sodium [4] First Databank, Inc. (n.d.). Drug Pricing Data. (Subscription-based access required for specific current data points).